{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:41:55Z","timestamp":1793900515400,"version":"4.8.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review provides an overview of the current treatments for systemic sclerosis-interstitial lung disease (SSc-ILD) and proposes a conceptual framework for disease management with case scenarios.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Broad treatment categories include traditional cytotoxic therapies, biologic disease-modifying rheumatic drugs, antifibrotic agents, autologous hematopoietic stem cell transplant, and lung transplantation. The optimal use of each option varies depending on SSc-ILD severity, progression, and comorbidities of individual patients. A high-quality randomized controlled trial demonstrated nintedanib's ability to retard decline of lung function in patients with limited and diffuse cutaneous disease, with established ILD. Tocilizumab, recently approved by the FDA, provides a unique intervention in those with early SSc associated with ILD with elevated acute-phase reactants: two well designed trials showed lung function preservation in phase 2 and phase 3 trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Stratifying patients based on key SSc-ILD characteristics (e.g. severity, risk of progression, comorbid disease presentation) may provide a useful guide for practitioners treating SSc-ILD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000795","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T01:04:30Z","timestamp":1616202270000},"page":"240-248","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":40,"title":["Treatment for systemic sclerosis-associated interstitial lung disease"],"prefix":"10.1097","volume":"33","author":[{"given":"David","family":"Roofeh","sequence":"first","affiliation":[{"name":"Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Lescoat","sequence":"additional","affiliation":[{"name":"Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Department of Internal Medicine and Clinical Immunology, Rennes University Hospital"},{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Sant\u00e9, Environnement et Travail) - UMR_S 1085, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/art.41246","article-title":"Current and future outlook on disease modification and defining low disease activity in systemic sclerosis","volume":"72","author":"Nagaraja","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/ard.2008.091710","article-title":"Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study","volume":"68","author":"Vonk","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acr.21583","article-title":"Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis","volume":"64","author":"Steele","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"(April)","key":"R8-20250526","first-page":"1","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.lpm.2014.08.002","article-title":"Interstitial lung disease in systemic sclerosis","volume":"43","author":"Wells","year":"2014","journal-title":"Press Medicale"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0034-1371541","article-title":"Interstitial lung disease in systemic sclerosis","volume":"35","author":"Wells","year":"2014","journal-title":"Semin Respir Crit Care Med"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir Res"},{"issue":"(2S)","key":"R12-20250526","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2397198320903208","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: lessons from clinical trials","volume":"5","author":"Roofeh","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/17476348.2019.1575732","article-title":"Scleroderma-related interstitial lung disease: principles of management","volume":"13","author":"Das","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00296-020-04515-6","article-title":"Is biological therapy in systemic sclerosis the answer?","volume":"40","author":"Misra","year":"2020","journal-title":"Rheumatol Int"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"Perelas","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"e000533","DOI":"10.1136\/rmdopen-2017-000533","article-title":"Haematopoietic stem cell transplantation in systemic sclerosis","volume":"4","author":"Walker","year":"2018","journal-title":"RMD Open"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/BOR.0000000000000546","article-title":"Lung transplantation in scleroderma: recent advances and lessons","volume":"30","author":"Jablonski","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2\u200ayears in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41584-018-0062-0","article-title":"Major lung complications of systemic sclerosis","volume":"14","author":"Denton","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"106389","DOI":"10.1016\/j.intimp.2020.106389","article-title":"Safety and efficacy of rituximab in systemic sclerosis: a systematic review and meta-analysis","volume":"83","author":"Tang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the treatment of systemic sclerosis\u2013related interstitial lung disease: a systematic review and meta-analysis","volume":"60","author":"Goswami","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R30-20250526","doi-asserted-by":"crossref","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis associated interstitial lung disease","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14397595.2019.1696505","article-title":"Nintedanib: new indication for systemic sclerosis-associated interstitial lung disease","volume":"30","author":"Kuwana","year":"2020","journal-title":"Mod Rheumatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/2397198319841842","article-title":"Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis\u2013associated interstitial lung disease","volume":"4","author":"Wollin","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous nonmyeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"Van Laar","year":"2014","journal-title":"JAMA"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.healun.2018.03.003","article-title":"Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study","volume":"37","author":"Prad\u00e8re","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.39021","article-title":"Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study","volume":"67","author":"Bernstein","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/BOR.0000000000000711","article-title":"Management of systemic sclerosis: the first five years","volume":"32","author":"Roofeh","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/BOR.0000000000000592","article-title":"Management of systemic sclerosis-associated interstitial lung disease","volume":"31","author":"Roofeh","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/art.34482","article-title":"A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis","volume":"64","author":"Steen","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3899\/jrheum.170055","article-title":"Scleroderma lung involvement, autoantibodies, and outcome prediction: the confounding effect of time","volume":"44","author":"Nihtyanova","year":"2017","journal-title":"J Rheumatol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS One"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1136\/annrheumdis-2019-215145","article-title":"Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis","volume":"78","author":"Becker","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - report from OMERACT CTD-ILD working group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R53-20250526","first-page":"1","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"9913","author":"Hoffmann-Vold","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","article-title":"Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society","volume":"8","author":"Hatabu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R56-20250526","first-page":"596","article-title":"Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review","volume":"57","author":"Teles","year":"2017","journal-title":"Rev Bras Ortop English Ed"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.semarthrit.2020.08.004","article-title":"Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"(Uf 04)","key":"R61-20250526","first-page":"0","article-title":"Autologous hematopoietic stem cell transplant in systemic sclerosis is associated with marked improvement in health-related quality of life","author":"Maltez","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1055\/s-2007-985613","article-title":"The spectrum of scleroderma lung disease","volume":"28","author":"Highland","year":"2007","journal-title":"Semin Respir Crit Care Med"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/17474124.2019.1561274","article-title":"Perspectives on the interlinked nature of systemic sclerosis and reflux disease","volume":"13","author":"Chwiesko","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1148\/rg.2015140334","article-title":"American Thoracic Society\u2013European Respiratory Society Classification of the idiopathic interstitial pneumonias: advances in knowledge since","volume":"35","author":"Sverzellati","year":"2015","journal-title":"Radiographics"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-018-0709-5","article-title":"An update on systemic sclerosis-associated pulmonary arterial hypertension: a review of the current literature","volume":"20","author":"Sundaram","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/BOR.0000000000000552","article-title":"Muscle disease in scleroderma","volume":"30","author":"Paik","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/rheumatology\/kev016","article-title":"Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling","volume":"54","author":"Man","year":"2015","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:20:02Z","timestamp":1748294402000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000795","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]}}}